Activation of peroxisome proliferator-activated receptors (PPARs), and particularly ofPPARα and PPARγ, using selective agonists, is currently used in the treatment of metabolic diseases such as hypertriglyceridemia and type 2 diabetes mellitus. This evidence concerns the gene PPARG and metabolic disease.